Chronic Obstructive Pulmonary Disease (COPD)

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and progressive, largely irreversible airflow limitation, caused by chronic inflammation of the airways and lung parenchyma that is most often driven by cigarette smoking.^[1] The cardinal symptoms are breathlessness, chronic cough, and sputum production; the hallmark functional finding is a post-bronchodilator FEV1/FVC ratio below the lower limit of normal (or below 0.7), confirming fixed airflow obstruction that bronchodilators improve but do not normalize.^[2]

COPD behaves as a systemic disease: breathlessness drives patients to restrict physical activity, which triggers a downward spiral of deconditioning, worsening dyspnea, and further inactivity. Because this cycle — not the spirometric abnormality alone — drives much of the disability in COPD, smoking cessation and optimal bronchodilation are the two interventions that most directly interrupt it, alongside pulmonary rehabilitation to reverse deconditioning that has already occurred.

Typical presentation

Progressive exertional dyspnea is the dominant symptom — insidious at onset, often minimized or attributed to aging or deconditioning by the patient, and progressive over years. Chronic cough (often productive, sometimes intermittent and non-productive) and regular sputum production frequently precede or accompany the dyspnea. Patients typically restrict physical activity to avoid breathlessness, which itself becomes a further source of functional decline.

Assessing symptom severity

Two validated tools quantify the impact of breathlessness and overall symptom burden, and both directly drive the GOLD ABE treatment groups (see Choose Initial Treatment).

Modified Medical Research Council (mMRC) dyspnea scale — the patient selects the single grade that best describes their breathlessness.^[3]

The COPD Assessment Test (CAT) is a complementary 8-item patient-completed questionnaire (each item scored 0-5, total 0-40) capturing a broader symptom burden than dyspnea alone — cough, phlegm, chest tightness, breathlessness on exertion, activity limitation, confidence leaving home, sleep, and energy.^[4] A CAT score of 10 or more, or an mMRC grade of 2 or more, defines "more symptoms" for GOLD group assignment.

Physical examination

Physical examination is relatively insensitive for diagnosis, especially in early disease — wheeze and signs of dyspnea may be the only findings. Signs of hyperinflation, hypoxemia, and pulmonary hypertension appear only in more advanced disease and should not be relied on to detect COPD early.

• Cigarette smoking — the dominant risk factor; risk is proportional to cumulative pack-year exposure.
• Heavy occupational exposure to dusts, chemicals, or fumes.
• Indoor and outdoor air pollution, including biomass fuel exposure.
• Alpha1-antitrypsin deficiency — an under-recognized genetic cause, associated with emphysema, liver disease, and panniculitis.
• Genetic variation more broadly — research suggests genetic factors influence both the presentation and severity of COPD independent of smoking history.
• Recurrent lower respiratory tract infections, particularly in childhood, which can impair lung development and lower peak attained lung function.
• A history of asthma — chronic, poorly controlled asthma is itself a risk factor for later fixed airflow obstruction.
• Older age.

Differentiating COPD from asthma

COPD and asthma are distinct disorders that are sometimes confused on initial presentation, although they may share treatable traits (e.g., eosinophilic inflammation, partial reversibility) and can coexist in the same patient.^[1]

History

• Characterize dyspnea onset, pattern, and severity (mMRC/CAT), chronic cough, and sputum production/volume/colour.
• Quantify smoking history in pack-years, and ask about occupational dust/chemical exposure and biomass fuel exposure.
• Ask specifically about alpha1-antitrypsin deficiency risk factors (early-onset disease, minimal smoking history, family history).
• Screen for comorbidities that share risk factors with, or worsen the course of, COPD: cardiovascular disease, osteoporosis, skeletal muscle dysfunction, pulmonary embolism, secondary polycythemia, depression/anxiety, malnutrition, pneumonia, malignancy, and metabolic syndrome.
• Obtain a full exacerbation history — hospitalizations, emergency visits, and courses of oral corticosteroids or antibiotics in the past year — since this directly determines GOLD group assignment (see Choose Initial Treatment).
• Assess impact on daily function and the social supports available.

Physical examination

Relatively insensitive for diagnosis, particularly early in disease; wheeze and signs of dyspnea may be the only findings. Signs of hyperinflation, hypoxemia, and pulmonary hypertension are late findings.

Spirometry — the gold standard for diagnosis

A post-bronchodilator FEV1/FVC ratio below 0.7 confirms persistent airflow limitation and is required to establish the diagnosis; a ratio below the lower limit of normal (LLN) is the more accurate criterion and avoids over-diagnosing COPD in older adults, in whom a fixed 0.7 cut-off can be falsely positive — LLN is the preferred measurement in Canada.^[2] A significant bronchodilator response — an increase in FEV1 of at least 12% and at least 200 mL after inhaled salbutamol — supports reversibility but does not exclude COPD, and its presence or absence should never be used alone to distinguish COPD from asthma.

Pre-bronchodilator spirometry can only be used to exclude a diagnosis of COPD, not to confirm one — a normal pre-bronchodilator FEV1/FVC rules COPD out, but an abnormal pre-bronchodilator result requires post-bronchodilator testing before the diagnosis can be made.

Spirometric grade describes the severity of airflow obstruction but no longer drives initial treatment selection on its own — see the GOLD ABE assessment in Choose Initial Treatment.

Additional investigations

• CBC — screens for polycythemia (a marker of chronic hypoxia) or anemia, either of which can worsen dyspnea.
• Chest x-ray — to exclude alternative diagnoses (lung cancer, bronchiectasis, tuberculosis), not to diagnose COPD itself.
• Pulse oximetry, with arterial blood gases if FEV1 <1 L or <40% predicted, SaO2 <92%, or there are clinical signs of respiratory failure or right heart failure.
• Alpha1-antitrypsin level in any patient under 65 years of age presenting with COPD, with fewer than 20 pack-years of smoking history, or with a strong family history of COPD.^[5]
• Blood eosinophil count (via CBC) — not needed for diagnosis, but essential once COPD is confirmed, since it is the key biomarker guiding whether an inhaled corticosteroid belongs in the regimen (see Choose Initial Treatment).
• Lung volumes, carbon monoxide diffusing capacity, and CT imaging are reserved for a marked discordance between the degree of airflow obstruction and perceived symptoms, or when surgical/interventional therapy is being considered — neither is a routine diagnostic test for uncomplicated COPD.

• Prevent disease progression.
• Decrease or eliminate breathlessness and other respiratory symptoms through optimal bronchodilation.
• Improve exercise tolerance and reverse activity-limitation-driven deconditioning.
• Reduce the frequency and severity of exacerbations.
• Improve health-related quality of life.
• Recognize and treat COPD comorbidities — cardiovascular disease, depression/anxiety, osteoporosis, and smoking-related malignancies.
• Reduce impairment and disability.
• Reduce mortality.

The GOLD ABE assessment (guides initial pharmacotherapy)

Once COPD is confirmed by spirometry, initial drug therapy is chosen using the number and severity of exacerbations in the past year together with current symptom burden (mMRC or CAT) — not spirometric grade alone.^[1]

Smoking cessation — the single highest-impact intervention

Advise and support cessation at every visit; this is the only intervention proven to slow the rate of lung function decline and reduce mortality in COPD, and its benefit exceeds that of any pharmacologic option.^[2] Sustained cessation (10 or more years) is associated with a progressively lower risk of acute exacerbations, proportional to smoke-free time. Offer pharmacotherapy (nicotine replacement therapy or varenicline — see Pharmacologic Treatment Options; bupropion is a further recognized alternative agent) alongside behavioural counselling at every attempt — do not rely on counselling or willpower alone.

Pulmonary rehabilitation, exercise, and education

Pulmonary rehabilitation is a comprehensive, patient-tailored intervention combining exercise training, education, and behaviour change, delivered by a multidisciplinary team (respiratory therapists, Certified Respiratory Educators, pharmacists, and other allied health professionals). Refer symptomatic patients early — benefit is seen across all stages of COPD severity, not only advanced disease.^[2] After an acute exacerbation, initiate or resume pulmonary rehabilitation within 4 weeks to reduce the risk of further exacerbations.

Encourage regular physical activity and reinforce pursed-lip breathing technique at every visit — patients with lower activity levels after hospital discharge are more likely to be readmitted, and deconditioning itself limits the effectiveness of pharmacologic treatment.

Vaccination

Ensure every patient with COPD is up to date on all age-appropriate immunizations, since respiratory infection is a major driver of exacerbations.^[7]

• Influenza: annual vaccination with an inactivated (killed) vaccine, given early in the fall — reduces exacerbations, hospitalization, and death in COPD. Avoid the live-attenuated intranasal vaccine in chronic lung disease.
• Pneumococcal: one dose of a pneumococcal conjugate vaccine (Pneu-C-20 or Pneu-C-21) for all adults with COPD aged 50 and older, regardless of prior vaccination with an earlier pneumococcal vaccine (Pneu-C-13, Pneu-C-15, or Pneu-P-23).^[7]
• Respiratory syncytial virus (RSV): strongly recommended for all adults 75 and older, and for adults 65-74 with an increased risk of severe RSV disease (which includes COPD). Strongly recommended regardless of age (18 and older) for anyone on home or chronic oxygen therapy — a group at particularly high risk of severe RSV disease.^[8]
• Tdap (tetanus, diphtheria, acellular pertussis): recommended for patients with COPD not vaccinated against pertussis in adolescence, given increased pertussis risk in chronic lung disease.
• Shingles (recombinant zoster vaccine): routine vaccination recommended per standard age-based adult immunization schedules.
• COVID-19: keep up to date with vaccination per current national recommendations.

Written action plan and self-management

Provide a written COPD action plan describing early warning signs of an exacerbation and the specific steps to take — but always combine it with structured education and case management; an action plan alone, without this support, has not been shown to reduce exacerbations or urgent care use.

Inhaler technique and device selection

Review inhaler technique at every visit — poor technique is common, often goes uncorrected, and directly undermines drug delivery regardless of which agent is prescribed. Choose the delivery device (pMDI with or without a spacer, dry powder inhaler, soft mist inhaler, or nebulizer) based on the patient's ability to use it correctly, consistently, and affordably; reserve nebulizers for patients who remain symptomatic despite maximal treatment with a correctly-used handheld device. Where possible, use one inhaler device type for all of a patient's COPD medications to simplify technique and improve adherence.

Other measures

• Minimize or eliminate exposure to air pollution and occupational dusts/chemicals.
• Address nutrition — both underweight and obese patients with COPD have worse outcomes; involve dietary support where indicated.
• Oscillating positive expiratory pressure (OCEP) devices (e.g., Aerobika) have limited supporting evidence to date and are not yet incorporated into Canadian or GOLD guideline recommendations — larger studies are needed before routine use can be recommended.
• In selected patients with advanced emphysema refractory to optimized medical therapy, surgical or bronchoscopic lung volume reduction, or lung transplantation may be appropriate — refer to a specialist COPD program for assessment.
• Palliative care approaches are effective for symptom control in advanced COPD and should be introduced alongside, not instead of, active disease management.

Pregnancy

Smoking cessation is the single most important intervention in a pregnant patient with COPD, or any pregnant smoker — pursue it more urgently than in the non-pregnant setting, using behavioural counselling first-line and NRT if counselling alone is insufficient, since the risk of continued smoking outweighs the risk of NRT itself. Inhaled short- and long-acting bronchodilators (SABA, SAMA, LABA, LAMA) are generally continued through pregnancy when needed for symptom control, since undertreated maternal hypoxemia poses a greater fetal risk than these agents. Apply the same eosinophil-guided principles for ICS as in the non-pregnant patient — do not withhold a clinically indicated ICS because of pregnancy. Data for roflumilast and theophylline in pregnancy are limited — avoid unless the treating specialist judges the benefit clearly outweighs the uncertainty. Varenicline has limited pregnancy safety data; NRT is generally the preferred pharmacotherapy for smoking cessation in pregnancy when counselling alone fails.

Breastfeeding

Inhaled bronchodilators and inhaled corticosteroids are compatible with breastfeeding given minimal systemic absorption. Theophylline passes into breast milk in clinically relevant amounts — monitor the infant for irritability or feeding difficulty if the mother requires theophylline. NRT is compatible with breastfeeding; take doses after a feed rather than immediately before when practical.

Pediatrics

COPD is fundamentally an adult-onset, cumulative-exposure disease — it is not diagnosed or treated in children, and none of the maintenance pharmacotherapy in this chapter has an established pediatric COPD dose. A child or adolescent with unexplained fixed airflow obstruction should be worked up for an alternative cause (e.g., cystic fibrosis, bronchopulmonary dysplasia, early-onset alpha1-antitrypsin deficiency) rather than treated as COPD.

Older adults

The majority of patients with COPD are older adults. Assess cognitive status and manual dexterity when selecting an inhaler device, since correct technique is essential to drug delivery regardless of severity. Review the cumulative anticholinergic burden when a LAMA is combined with other anticholinergic medications the patient may already be taking for unrelated conditions (e.g., overactive bladder, some antidepressants). No dose adjustment of tiotropium or umeclidinium/vilanterol is required specifically for age.

Renal impairment

Most inhaled LAMAs (tiotropium, umeclidinium, glycopyrronium) require no dose adjustment in mild-moderate renal impairment, but should be used with caution and closely monitored for anticholinergic side effects in severe renal impairment, since renal clearance contributes meaningfully to their elimination. Sulfamethoxazole/trimethoprim and the fluoroquinolones used for exacerbations require renal dose adjustment. Theophylline itself is not renally cleared, but many drugs that interact with it are.

Hepatic impairment

Theophylline clearance is reduced in hepatic impairment — use lower starting doses and closely monitor serum levels. Roflumilast is not recommended in moderate-to-severe hepatic impairment (Child-Pugh B or C).

Alpha1-antitrypsin deficiency

A distinct COPD subpopulation requiring specialist confirmation and consideration of intravenous augmentation therapy in addition to standard COPD pharmacotherapy — refer to a specialist program once a low alpha1-antitrypsin level is confirmed.^[5]

• Individualize the follow-up interval — more frequent in patients with more severe disease, longer in milder disease.
• Reassess symptom burden (mMRC or CAT) and exacerbation frequency at every visit.
• Repeat spirometry at least annually.
• Check inhaler technique and adherence at every visit — one of the highest-yield things a pharmacist can do at each encounter.
• Reassess smoking status and readiness to quit at every visit, regardless of how many prior attempts have failed.
• Screen for and actively manage comorbidities (cardiovascular disease, osteoporosis, depression/anxiety, nutrition/weight) — these influence health status and mortality independently of airflow obstruction severity.
• Confirm vaccination status is current.
• For a patient on long-term oxygen therapy, non-invasive ventilation, or awaiting interventional/surgical assessment, coordinate structured specialist follow-up alongside routine primary/pharmacy care.
• Update the written action plan at each visit and confirm the patient knows when and how to use it.

1. Before escalating any therapy, confirm inhaler technique is correct, confirm adherence, and screen for comorbidities that could be mimicking or worsening symptoms (e.g., heart failure, anxiety, deconditioning).
2. Identify the predominant treatable trait driving inadequate control — persistent dyspnea/activity limitation, or ongoing exacerbations — since the escalation pathway differs for each; if both are present, follow the exacerbation pathway.^[1]
3. Dyspnea pathway: if breathless on bronchodilator monotherapy, add a second long-acting bronchodilator class to reach LABA+LAMA. If dyspnea persists on LABA+LAMA despite confirmed technique and adherence, consider switching inhaler device or molecule within the same class, escalate non-pharmacologic therapy (pulmonary rehabilitation), and consider adding ensifentrine — a novel inhaled PDE3/4 inhibitor — where accessible; it is not currently available in Canada. Investigate and treat non-COPD causes of dyspnea (cardiac, anemia, deconditioning, anxiety) before escalating COPD-specific therapy further.
4. Exacerbation pathway: if exacerbating on bronchodilator monotherapy, escalate to LABA+LAMA. If a moderate or severe exacerbation occurs on LABA+LAMA, escalate to LABA+LAMA+ICS triple therapy — a beneficial ICS response is more likely with blood eosinophils ≥100 cells/µL, with greater benefit at higher counts.
5. If exacerbations continue on LABA+LAMA with blood eosinophils under 100 cells/µL, consider adding azithromycin prophylaxis (in patients who are not currently smoking) or roflumilast (in patients with FEV1 <50% predicted, chronic bronchitis symptoms, and a prior exacerbation requiring hospitalization).
6. If exacerbations continue despite triple therapy, in patients with blood eosinophils ≥300 cells/µL, consider adding dupilumab (preferred if a chronic bronchitis phenotype is present) or mepolizumab (effective with or without a chronic bronchitis phenotype); azithromycin and roflumilast remain options per the criteria above regardless of eosinophil count.
7. Do not withdraw the ICS component from a patient stable on triple therapy unless it was started inappropriately, there has been no response, or the patient has significant side effects or recurrent pneumonia — de-escalation is more likely to be followed by exacerbations if blood eosinophils remain ≥300 cells/µL.
8. After any exacerbation, review and optimize the entire management plan — inhaler technique, adherence, non-pharmacologic measures, and vaccination status — and refer to pulmonary rehabilitation within 4 weeks.

• Diagnosing COPD from symptoms or a chest x-ray alone, without confirmatory post-bronchodilator spirometry.
• Using a pre-bronchodilator-only spirometry result to confirm COPD — it can only be used to exclude the diagnosis, not establish it.
• Starting or continuing ICS/LABA dual therapy without a LAMA, or ICS monotherapy — neither is recommended in COPD.
• Prescribing antibiotics for a mild exacerbation without purulent sputum or the other cardinal symptoms that justify their use.
• Treating pharmacotherapy as sufficient on its own and skipping smoking-cessation counselling at follow-up visits.
• Continuing oral corticosteroids beyond the acute exacerbation course — there is no role for chronic maintenance oral corticosteroid therapy in COPD.
• Unnecessarily tapering a short (under 2-week) oral corticosteroid course for an exacerbation.
• Never checking or correcting inhaler technique at follow-up.
• Prescribing duplicate therapy from the same drug class (e.g., a separate LAMA product alongside a LAMA/LABA combination inhaler).
• Missing alpha1-antitrypsin deficiency testing in a younger patient with COPD and a minimal smoking history.
• Withdrawing the ICS component from a triple-therapy patient with blood eosinophils ≥300 cells/µL without recognizing the elevated risk of subsequent exacerbations.
• Over-titrating supplemental oxygen in a hypoventilating (hypercapnic) patient without monitoring for worsening hypercarbic hypoxia.

How to use this table: doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment. COPD is an adult-onset disease — pediatric dosing is not established for any agent in this table and none is included. Select any drug name to open its complete Pharmasist Drug Database page.

Short-acting bronchodilators

For as-needed symptom relief in every patient, regardless of GOLD group.

Long-acting bronchodilators — beta2-agonists (LABA)

Offered as monotherapy mainly when a LAMA cannot be tolerated or adherence with twice-daily dosing is a concern.

Long-acting bronchodilators — muscarinic antagonists (LAMA)

First-line long-acting bronchodilator class for Group B/E — reduces exacerbations and hospitalizations across the class.

Combination LAMA/LABA

Preferred over ICS/LABA when starting combination bronchodilator therapy, for symptom control and exacerbation prevention alike.

Combination ICS/LABA

ICS/LABA dual therapy without a LAMA is not encouraged in COPD (see Choose Initial Treatment) — included here for reference and for patients already established on this combination.

Combination ICS/LAMA/LABA (triple therapy)

Reserve for Group E patients with blood eosinophils ≥300 cells/µL, or patients already on LABA+LAMA who continue to exacerbate with eosinophils ≥100 cells/µL. Use a single-inhaler triple therapy product rather than combining separate inhalers, since compliance with multi-inhaler triple therapy is consistently poor.

Phosphodiesterase-4 (PDE4) inhibitor

Methylxanthine

Reserve for severe symptoms despite optimized triple therapy; consult a specialist at this stage of disease. Narrow therapeutic index.

Mucolytic

Prophylactic macrolide

For patients with moderate-severe COPD who have had 1 or more moderate or severe exacerbations in the past year despite optimal inhaled therapy. Confirm baseline QTc and hearing; weigh antimicrobial resistance risk; ideal duration has not been established.

Biologics (add-on for eosinophilic COPD)

Reserve for patients inadequately controlled on optimal inhaled triple therapy (or LABA+LAMA if ICS is not appropriate) with blood eosinophils ≥300 cells/µL.

Smoking-cessation pharmacotherapy

Offer alongside behavioural counselling at every quit attempt — pharmacotherapy roughly doubles quit success compared with counselling alone.

Systemic corticosteroid (acute exacerbation only)

No role for chronic maintenance oral corticosteroid therapy in COPD. Tapering is unnecessary for courses under 2 weeks.

Long-term oxygen therapy (intervention, not a drug)

Pulmonary rehabilitation (intervention, not a drug)

Oral antibiotics for acute exacerbations

Reserve antibiotics for exacerbations meeting at least 2 of the 3 cardinal symptoms (increased dyspnea, increased sputum volume, increased sputum purulence), or for any exacerbation severe enough to require invasive mechanical ventilation. Choose empirically using the patient's exacerbation frequency and recent antibiotic exposure, and switch to a different antibiotic class if the same class was used within the past 3 months or if the patient has not responded within 24-36 hours.

Penicillins

Sulfonamide combination

Tetracycline

Cephalosporin

Fluoroquinolones

Reserve for higher-risk exacerbations; avoid in myasthenia gravis and with other QTc-prolonging drugs.

Macrolides

Vaccines

See Non-Pharmacologic Treatment for the full recommendation set and Canadian eligibility criteria.